Unknown

Dataset Information

0

Therapeutic dosages of aspirin counteract the IL-6 induced pro-tumorigenic effects by slowing down the ribosome biogenesis rate.


ABSTRACT: Chronic inflammation is a risk factor for the onset of cancer and the regular use of aspirin reduces the risk of cancer development. Here we showed that therapeutic dosages of aspirin counteract the pro-tumorigenic effects of the inflammatory cytokine interleukin(IL)-6 in cancer and non-cancer cell lines, and in mouse liver in vivo. We found that therapeutic dosages of aspirin prevented IL-6 from inducing the down-regulation of p53 expression and the acquisition of the epithelial mesenchymal transition (EMT) phenotypic changes in the cell lines. This was the result of a reduction in c-Myc mRNA transcription which was responsible for a down-regulation of the ribosomal protein S6 expression which, in turn, slowed down the rRNA maturation process, thus reducing the ribosome biogenesis rate. The perturbation of ribosome biogenesis hindered the Mdm2-mediated proteasomal degradation of p53, throughout the ribosomal protein-Mdm2-p53 pathway. P53 stabilization hindered the IL-6 induction of the EMT changes. The same effects were observed in livers from mice stimulated with IL-6 and treated with aspirin. It is worth noting that aspirin down-regulated ribosome biogenesis, stabilized p53 and up-regulated E-cadherin expression in unstimulated control cells also. In conclusion, these data showed that therapeutic dosages of aspirin increase the p53-mediated tumor-suppressor activity of the cells thus being in this way able to reduce the risk of cancer onset, either or not linked to chronic inflammatory processes.

SUBMITTER: Brighenti E 

PROVIDER: S-EPMC5325359 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Therapeutic dosages of aspirin counteract the IL-6 induced pro-tumorigenic effects by slowing down the ribosome biogenesis rate.

Brighenti Elisa E   Giannone Ferdinando Antonino FA   Fornari Francesca F   Onofrillo Carmine C   Onofrillo Carmine C   Govoni Marzia M   Montanaro Lorenzo L   Treré Davide D   Derenzini Massimo M  

Oncotarget 20160901 39


Chronic inflammation is a risk factor for the onset of cancer and the regular use of aspirin reduces the risk of cancer development. Here we showed that therapeutic dosages of aspirin counteract the pro-tumorigenic effects of the inflammatory cytokine interleukin(IL)-6 in cancer and non-cancer cell lines, and in mouse liver in vivo. We found that therapeutic dosages of aspirin prevented IL-6 from inducing the down-regulation of p53 expression and the acquisition of the epithelial mesenchymal tra  ...[more]

Similar Datasets

| S-EPMC4793216 | biostudies-literature
| S-EPMC7320017 | biostudies-literature
| S-EPMC10484202 | biostudies-literature
| S-EPMC4252078 | biostudies-literature
| S-EPMC8051945 | biostudies-literature
| S-EPMC6517405 | biostudies-literature
| S-EPMC6558755 | biostudies-literature
| S-EPMC6877332 | biostudies-literature
| S-EPMC6356843 | biostudies-literature
| S-EPMC8528280 | biostudies-literature